Details

Last Funding Type

Debt Financing

Last Funding Money Raised

€40M

Industries

Biopharma,Biotechnology,Medical Device,Pharmaceutical

Founded date

Jan 1, 2004

Number Of Employee

51 - 100

Operating Status

Active

ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company.

Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.